公开(公告)号：US20210292308A1

公开(公告)日：2021-09-23

申请号：US16606043

申请日：2018-04-17

Applicant: TAKEDA PHARMACEUTICAL COMPANY LIMITED

Inventor： Shinobu SASAKI ,  Masaki SETO ,  Kazuaki TAKAMI ,  Haruhi ANDO

IPC: C07D405/14 ,  C07D405/04 ,  C07D409/14 ,  A61P1/10

Abstract: The present invention aims to provide a compound that may be useful for the prophylaxis or treatment of constipation and the like. The present invention provides a compound represented by the following formula (I): wherein each symbol is as described in the specification, salt thereof.

公开(公告)号：US20170174682A1

公开(公告)日：2017-06-22

申请号：US15452003

申请日：2017-03-07

Applicant: TAKEDA PHARMACEUTICAL COMPANY LIMITED

Inventor： Masato YOSHIDA ,  Hiroyuki NAGAMIYA ,  Yusuke OHBA ,  Masaki SETO ,  Takatoshi YOGO ,  Satoshi SASAKI ,  Norihito TOKUNAGA ,  Kazuyoshi ASO

IPC: C07D471/04 ,  C07D519/00

CPC classification number: C07D471/04 ,  C07D519/00

Abstract: Provided is a compound or a salt thereof, which has an excellent JAK inhibitory action, and is useful as a prophylactic or therapeutic agent for autoimmune diseases (rheumatoid arthritis, psoriasis, inflammatory bowel disease, Sjogren's syndrome, Behcet's syndrome, multiple sclerosis, systemic lupus erythematosus, etc.), cancer (leukemia, uterine leiomyosarcoma, prostate cancer, multiple myeloma, cachexia, myelofibrosis, etc.) and the like. The present invention relates to a compound represented by the formula (I) wherein each symbol is as defined in the present specification, or a salt thereof.

公开(公告)号：US20240309016A1

公开(公告)日：2024-09-19

申请号：US18606857

申请日：2024-03-15

Applicant: TAKEDA PHARMACEUTICAL COMPANY LIMITED

Inventor： Mitsunori KONO ,  Yusuke SASAKI ,  Yuya OGURO ,  Zenichi IKEDA ,  Osamu KUBO ,  Masaki SETO ,  Toru YAMASHITA ,  Makoto KAMATA ,  Kenjiro SATO ,  Matthew Thomas REYNOLDS ,  Kazuaki TAKAMI ,  Asato KINA ,  Takafumi YUKAWA ,  Minoru NAKAMURA ,  Taku KAMEI ,  Hiroyuki KAKEI ,  Fumie YAMAGUCHI ,  Tomohiro OHASHI ,  Keiko KAKEGAWA ,  Takuto KOJIMA ,  Florian PÜNNER ,  Masataka MURAKAMI ,  Takahiko TANIGUCHI ,  Tatsuki KOIKE ,  Yuichi KAJITA ,  Yuhei MIYANOHANA ,  Kohei TAKEUCHI ,  Yoshiteru ITO ,  Norihito TOKUNAGA ,  Yasushi HATTORI ,  Eiji KIMURA ,  Martin Alexander PAWLICZEK ,  Marilena PIRA ,  Shuhei IKEDA ,  Noriyuki TEZUKA ,  Yoshikazu WATANABE ,  Kevin CURRAN ,  Nicolle DOERING ,  Maria HOPKINS ,  Ben JOHNSON ,  Andre KIRYANOV ,  Jon LAM ,  Sean MURPHY ,  Natasha O'ROURKE ,  Holly REICHARD ,  Paul TANIS ,  Yunlong ZHANG

IPC: C07D498/14 ,  A61K31/407 ,  A61K31/437 ,  A61P25/26 ,  C07D498/04

CPC classification number: C07D498/14 ,  A61K31/407 ,  A61K31/437 ,  A61P25/26 ,  C07D498/04

Abstract: The present invention provides a heterocyclic compound having an orexin type 2 receptor agonist activity.
A compound represented by the formula (I):




wherein each symbol is as described in the specification, or a salt thereof has an orexin type 2 receptor agonist activity, and is useful as an agent for the prophylaxis or treatment of narcolepsy.

公开(公告)号：US20220023207A1

公开(公告)日：2022-01-27

申请号：US17298460

申请日：2019-11-29

Applicant: Kyoto University ,  Takeda Pharmaceutical Company Limited

Inventor： Akitsu HOTTA ,  Naoko ISHIHARA ,  Ryuichi NISHIGAKI ,  Masaki SETO

IPC: A61K9/08 ,  A61K38/46 ,  A61K47/22 ,  A61K47/26 ,  A61K47/24 ,  A61K31/7088 ,  A61K47/18 ,  A61K47/16 ,  A61K47/12 ,  A61K47/10

Abstract: The present invention provides a means excellent in efficiency of introduction of a nucleic acid, a protein, a complex thereof, or the like into cells, in particular a method using a solution for transduction. In the method for transducing a molecule(s) of interest into a cell according to the present invention, comprising a step of contacting the cell with the molecule(s) of interest and a solution for transduction according to the present invention, the solution for transduction contains: at least one of the following (A1) to (A5); and (B) a salt: (A1) a compound represented by formula (I) excluding a predetermined compound, or a salt thereof; (A2) a compound represented by formula (II), or a salt thereof; (A3) a nucleic-acid base or the like, or a salt thereof; (A4) a compound represented by formula (III), or a salt thereof, excluding malic acid; and (A5) at least one selected from the group consisting of creatinine, hydroxyproline, 1,3-butanediol, trientine, D-cellobiose, 1,3-dimethylurea, pantolactone and trimethadione, or a salt thereof.

公开(公告)号：US20160264536A1

公开(公告)日：2016-09-15

申请号：US15031505

申请日：2014-10-22

Applicant: Takeda Pharmaceutical Company Limited

Inventor： Masaki SETO ,  Yoshihiro BANNO ,  Toshihiro IMAEDA ,  Yuichi KAJITA ,  Tomoko ASHIZAWA ,  Masanori KAWASAKI ,  Shinji NAKAMURA ,  Satoshi MIKAMI ,  Izumi NOMURA ,  Takahiko TANIGUCHI ,  Shogo MARUI

IPC: C07D277/56 ,  C07D403/12 ,  C07D239/28 ,  C07D403/04 ,  C07D239/47 ,  C07D239/36 ,  C07D239/52 ,  C07D241/24 ,  C07D498/08 ,  C07D413/04 ,  C07D405/04 ,  C07D401/04 ,  C07D417/04 ,  C07D409/04 ,  C07D401/12 ,  C07D239/42

CPC classification number: C07D277/56 ,  C07D239/28 ,  C07D239/36 ,  C07D239/42 ,  C07D239/47 ,  C07D239/48 ,  C07D239/52 ,  C07D239/54 ,  C07D239/56 ,  C07D241/24 ,  C07D241/26 ,  C07D277/20 ,  C07D401/04 ,  C07D401/06 ,  C07D401/12 ,  C07D403/04 ,  C07D403/12 ,  C07D405/04 ,  C07D409/04 ,  C07D413/04 ,  C07D413/14 ,  C07D417/04 ,  C07D417/14 ,  C07D498/04 ,  C07D498/08

Abstract: The problem of the present invention is to provide a compound having a PDE2A inhibitory action, and useful as a prophylactic or therapeutic drug for schizophrenia, Alzheimer's disease and the like. The present invention relates to a compound represented by the formula (I): wherein each symbol is as described in the DESCRIPTION, or a salt thereof.

Abstract translation: 其中每个符号如说明书中所述或其盐。